Study reaffirms the Foundation’s commitment to advance solutions to the growing challenge of antibiotic resistance
Site Search
The Cystic Fibrosis Foundation awarded up to $4.7 million to EnBiotix Inc. to study the potential use of inhaled colistin as an additional option to treat Pseudomonas infections in people with cystic fibrosis who are not responding to current treatments.
Investment will support discovery research of a novel Gene CodingTM approach that could benefit all people with CF regardless of their mutation
The Cystic Fibrosis Foundation awarded up to $3.5 million to Arrevus Inc. to test a potential treatment for pulmonary exacerbations in people with cystic fibrosis in a late phase clinical trial.
Breadth of expertise in business, philanthropy, community engagement, and venture capital to help advance Foundation’s mission
Groups urging need for revitalizing antimicrobial development call for passage of the bill this year
Brown to join Foundation in April 2023, bringing more than 20 years of experience in nonprofit communications and journalism, with a focus on health and science
Human resources veteran Massenburg brings more than 20 years of leadership experience in nonprofit and business sectors
The Foundation, in collaboration with external community advisors, finalizes recommendations in area of Community to help foster more inclusion and improve the experiences of Black people living with and impacted by cystic fibrosis.
A transformative leader for more than two decades, Marshall will transition to advisory role